Feverfew has a long history as a folk remedy for joint pain, but the clinical evidence for arthritis is disappointing. The only double-blind, placebo-controlled trial testing feverfew in rheumatoid arthritis, published in the Annals of the Rheumatic Diseases, found no meaningful differences in pain, stiffness, grip strength, or inflammatory markers between the feverfew group and the placebo group over six weeks. That doesn’t mean the herb is biologically inert. Its active compound shows real anti-inflammatory activity in lab studies. But if you’re considering feverfew for arthritis, you should understand both what it does at a cellular level and what it has (and hasn’t) done for actual patients.
Why Feverfew Looks Promising in the Lab
The key compound in feverfew, called parthenolide, blocks one of the body’s central inflammation switches. This switch controls the production of several proteins that drive joint swelling and cartilage breakdown, including the same inflammatory signals targeted by conventional arthritis drugs. In cartilage cells specifically, parthenolide reduces the production of enzymes that chew through the protective matrix surrounding joints. It also suppresses signals that activate osteoclasts, the cells responsible for bone erosion in inflammatory arthritis.
These aren’t trivial effects. Parthenolide also dials down the production of nitric oxide and COX-2, two molecules heavily involved in pain and inflammation. On paper, this profile looks like it should translate into joint relief. The problem is that lab-dish results and human outcomes don’t always align, especially when the compound has to survive digestion, reach joint tissue in adequate concentrations, and compete with the complexity of a full-blown autoimmune disease.
What Clinical Trials Actually Show
The one rigorous human trial for rheumatoid arthritis measured everything you’d want: pain scores, morning stiffness, grip strength, inflammatory blood markers like C-reactive protein, and immune markers including rheumatoid factor. After six weeks of oral feverfew, none of these improved compared to placebo. The researchers concluded there was no apparent benefit.
This is a single trial with a relatively short duration, so it’s not the final word. But it’s the best evidence available, and it’s not encouraging. Feverfew’s more established use is for migraine prevention, where multiple trials show modest benefit. For arthritis, herbalists in Great Britain have used it traditionally for “rheumatism” and general aches, but tradition alone doesn’t confirm effectiveness.
How People Typically Take It
If you still want to try feverfew for joint symptoms, here’s what the practical use looks like. Feverfew comes in several forms: dried leaf capsules, standardized extract capsules, teas, tinctures, and occasionally fresh leaves. Standardized capsules are the most common choice because they deliver a consistent amount of parthenolide, which varies wildly in raw plant material.
Most feverfew products are standardized to contain a specific percentage of parthenolide, and this is worth checking on the label. Products without standardization may contain very little of the active compound. Fresh leaves are sometimes chewed directly, a traditional method, but they frequently cause mouth ulcers and tongue irritation. Capsules sidestep that problem entirely.
Results from feverfew, in the conditions where it does show benefit, typically take four to six weeks of consistent daily use before anything noticeable happens. If you’re going to test it, plan on at least that long before evaluating whether it’s helping.
Side Effects and Withdrawal
Feverfew is generally well tolerated at standard doses, but it does carry some specific risks. The most common side effects are mild digestive upset and, with fresh leaf use, sores inside the mouth. Some long-term users report a rebound effect when they stop abruptly, sometimes called “post-feverfew syndrome,” which can include headaches, anxiety, muscle stiffness, and joint pain. If you’ve been taking it regularly, tapering off gradually over a week or two is a reasonable approach.
Who Should Avoid Feverfew
Feverfew slows platelet activity, meaning it affects how your blood clots. If you take blood thinners like warfarin or daily aspirin, adding feverfew increases bleeding risk. The same caution applies to NSAIDs like ibuprofen and naproxen, which many arthritis patients already use, since combining them with feverfew could compound effects on both the stomach lining and clotting.
Pregnant women should not take feverfew because it may stimulate uterine contractions. Safety during breastfeeding is unknown. Children under two should not use it. If you’re allergic to daisies, chamomile, ragweed, or other plants in the Asteraceae family, feverfew may trigger an allergic reaction since it belongs to the same botanical group.
Realistic Expectations
The honest picture is this: feverfew contains a compound with genuine anti-inflammatory properties that affect the specific pathways involved in arthritis. But the one clinical trial testing it in rheumatoid arthritis patients found no benefit over placebo. It’s possible that higher doses, longer treatment periods, or better-absorbed formulations could change that picture, but right now the evidence doesn’t support feverfew as a reliable arthritis treatment. If you choose to try it anyway, standardized capsules taken daily for at least six weeks represent the most reasonable approach, provided you don’t fall into any of the groups that should avoid it.